1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
2. Deininger, M.; Buchdunger, E.; Druker, B. J. The Development of Imatinib as a Therapeutic Agent for Chronic Myeloid Leukemia. Blood 2005, 105, 2640−2653.
3. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a Rationally Developed, Targeted Anticancer Drug. Nat. Rev. Drug Discovery 2002, 1, 493−502.
4. Lin, Y.-L.; Meng, Y.; Jiang, W.; Roux, B. Explaining why Gleevec is a Specific and Potent Inhibitor of Abl Kinase. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 1664−1669.
5. Sirvent, J. A.; Lücking, U. Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates. ChemMedChem 2017, 12, 487−501.
6. Qiu, Y.; Kung, H. J. Signaling network of the Btk family kinases. Oncogene. 2000, 19, 5651- 5661.
7. Kurosaki, T.; Hikida, M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev.2009, 228, 132-148.
8. Akinleye, A.; Chen, Y.; Mukhi, N.; Song, Y.; Liu, D. Ibrutinib and novel BTK inhibitors in clinical development. J. Hematol. Oncol. 2013, 6, 59.
9. Genevier, H, C,; Hinshelwood, S.; Gaspar, H. B.; Rigley, K. P.; Brown, D.; Saeland, S.; Rousset, F.; Levinsky, R. J.; Callard, R. E. Expression of Bruton's tyrosine kinase protein within the B cell lineage. Eur J Immunol. 1994, 24, 3100- 3105.
10. Khan, W. N. Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase. Immunol. Res. 2001, 23, 147−156.
11. Liu, Y.; Zhou, G.; Zhang, B.; Liu, Y. Bruton’s tyrosine kinase: structure and functions, expression and mutations. Gene Technol. 2013, 2, 106.
12. Tsukada, S.; Saffran, D. C.; Rawlings, D. J.; Parolini, O.; Allen, R. C.; Klisak, I.; Sparkes, R. S.; Kubagawa, H.; Mohandas, T. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993, 72, 279-290.
13. Conley, M. E,; Rohrer, J.; Rapalus, L.; Boylin, E. C.; Minegishi, Y. Defects in early B-cell development: comparing the consequences of abnormalities in pre-BCR signaling in the human and the mouse. Immunol Rev. 2000, 178, 75-90.
14. Nomura, K.; Kanegane, H.; Karasuyama, H.; Tsukada, S.; Agematsu, K.; Murakami, G.; Sakazume, S.; Sako, M.; Tanaka, R.; Kuniya, Y.; Komeno, T.; Ishihara, S.; Hayashi, K.; Kishimoto, T.; Miyawaki, T. Genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into a later stage of pre-B cells in the B-cell differentiation pathway. Blood. 2000, 96, 610- 617.
15. Satterthwaite, A. B.; Witte, O. N. The Role of Bruton’s Tyrosine Kinase in B-cell Development and Function: a Genetic Perspective. Immunol. Rev. 2000, 175, 120−127
16. Kurosaki, T. Functional dissection of BCR signaling pathways. Curr. Opin. Immunol. 2000, 12, 276−281.
17. Pal Singh, S.; Dammeijer, F.; Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol. Cancer 2018, 17, 57.
18. Hendriks, R. W.; Yuvaraj, S.; Kil, L. P. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat. Rev. Cancer 2014, 14, 219−232.
19. Davis, R. E.; Ngo, V. N.; Lenz, G.; Tolar, P.; Young, R. M.; Romesser, P. B.; Kohlhammer, H.; Lamy, L.; Zhao, H.; Yang, Y.; Xu, W.; Shaffer, A. L.; Wright, G.; Xiao, W.; Powell, J.; Jiang, J.- k.; Thomas, C. J.; Rosenwald, A.; Ott, G.; Muller-Hermelink, H. K.; Gascoyne, R. D.; Connors, J. M.; Johnson, N. A.; Rimsza, L. M.; Campo, E.; Jaffe, E. S.; Wilson, W. H.; Delabie, J.; Smeland, E. B.; Fisher, R. I.; Braziel, R. M.; Tubbs, R. R.; Cook, J. R.; Weisenburger, D. D.; Chan, W. C.; Pierce, S. K.; Staudt, L. M. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463, 88– 92.
20. Herishanu, Y.; Perez-Galan, P.; Liu, D.; Biancotto, A.; Pittaluga, S.; Vire, B.; Gibellini, F.; Njuguna, N.; Lee, E.; Stennett, L.; Raghavachari, N.; Liu, P.; McCoy, J. P.; Raffeld, M.; Stetler- Stevenson, M.; Yuan, C.; Sherry, R.; Arthur, D. C.; Maric, I.; White, T.; Marti, G. E.; Munson, P.; Wilson, W. H.; Wiestner, A. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011, 117, 563-574.
21. Ellmeier, W.; Abramova, A.; Schebesta, A. Tec family kinases: regulation of FceRI-mediated mast-cell activation. FEBS J. 2011, 278, 1990−2000.
22. Nimmerjahn, F.; Ravetch, J.V.; Fcgamma receptors as regulators of immune responses. Nature Rev Immunol. 2008, 8, 34-47.
23. Pan, Z.; Scheerens, H.; Li, S. J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C.; Grothaus, P. G.; Jeffery, D. A.; Spoerke, J. M.; Honigberg, L. A.; Young, P. R.; Dalrymple, S. A.; Palmer, J. T. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem 2007, 2, 58– 61.
24. Honigberg, L. A.; Smith, A. M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D. H.; Miller, R. A.; Buggy, J. J. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 13075-13080.
25. Byrd, J. C.; Harrington, B.; O’Brien, S.; Jones, J. A.; Schuh, A.; Devereux, S.; Chaves, J.; Wierda, W. G.; Awan, F. T.; Brown, J. R.; Hillmen, P.; Stephens, D. M.; Ghia, P.; Barrientos, J. C.; Pagel, J. M.; Woyach, J.; Johnson, D.; Huang, J.; Wang, X.; Kaptein, A.; Lannutti, B. J.; Covey, T.; Fardis, M.; McGreivy, J.; Hamdy, A.; Rothbaum, W.; Izumi, R.; Diacovo, T. G.; Johnson, A. J.; Furman, R. R. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2016, 374, 323– 332.
26. Walter, H. S.; Rule, S. A.; Dyer, M. J. S.; Karlin, L.; Jones, C.; Cazin, B.; Quittet, P.; Shah, N.; Hutchinson, C. V.; Honda, H.; Duffy, K.; Birkett, J.; Jamieson, V.; Courtenay-Luck, N.; Yoshizawa, T.; Sharpe, J.; Ohno, T.; Abe, S.; Nishimura, A.; Cartron, G.; Morschhauser, F.; Fegan, C.; Salles, G. A phase I clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 2016, 127, 411– 419.
27. Guo, Y.; Liu, Y.; Hu, N.; Yu, D.; Zhou, C.; Shi, G.; Zhang, B.; Wei, M.; Liu, J.; Luo, L.; Tang, Z.; Song, H.; Guo, Y.; Liu, X.; Su, D.; Zhang, S.; Song, X.; Zhou, X.; Hong, Y.; Chen, S.; Cheng, Z.; Young, S.; Wei, Q.; Wang, H.; Wang, Q.; Lv, L.; Wang, F.; Xu, H.; Sun, H.; Xing, H.; Li, N.; Zhang, W.; Wang, Z.; Liu, G.; Sun, Z.; Zhou, D.; Li, W.; Liu, L.; Wang, L.; Wang, Z. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase. J. Med. Chem. 2019, 62, 7923– 7940.
28. Liu, Q.; Sabnis, Y.; Zhao, Z.; Zhang, T.; Buhrlage, S. J.; Jones, L. H.; Gray, N. S. Developing Irreversible Inhibitors of the Protein Kinase Cysteinome. Chem. Biol. 2013, 20, 146-159.
29. Barf, T.; Kaptein, A. Irreversible protein kinase inhibitors: balancing the benefits and risks. J. Med. Chem. 2012, 55, 6243-6262.
30. Barf, T.; Covey, T.; Izumi, R.; van de Kar, B.; Gulrajani, M.; van Lith, B.; van Hoek, M.; de Zwart, E.; Mittag, D.; Demont, D.; Verkaik, S.; Krantz, F.; Pearson, P. G.; Ulrich, R.; Kaptein, A. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. J. Pharmacol. Exp. Ther. 2017, 363, 240–252.
31. Johnson, A. R.; Kohli, P. B.; Katewa, A.; Gogol, E.; Belmont, L.; Choy, R.; Penuel, E.; Burton, L.; Eigenbrot, C.; Yu, C.; Ortwine, D. F.; Bowman, K.; Franke, Y.; Tam, C.; Estevez, A.; Mortara, K.; Wu, J.; Li, H.; Lin, M.; Bergeron, P.; Crawford, J. J.; Young, W. B. Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations. ACS Chem. Biol. 2016, 11, 2897-2907.
32. Reiff, S. D.; Mantel, R.; Smith, L. L.; Greene, J. T.; Muhowski, E. M.; Fabian, C. A.; Goettl, V. M.; Tran, M.; Harrington, B. K.; Rogers, K. A.; Awan, F. T.; Maddocks, K.; Andritsos, L.; Lehman, A. M.; Sampath, D.; Lapalombella, R.; Eathiraj, S.; Abbadessa, G.; Schwartz, B.; Johnson, A. J.; Byrd, J. C.; Woyach, J. A. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discovery 2018, 8 , 1300– 1315.
33. Zhao, Z.; Wu, H.; Wang, L.; Liu, Y.; Knapp, S.; Liu, Q.; Gray, N. S. Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? ACS Chem. Biol. 2014, 9, 1230-1241.
34. Sawa, M. Strategies for the Design of Selective Protein Kinase Inhibitors. Mini-Rev. Med. Chem.2008, 8, 1291-1297.
35. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2, 358-364.
36. Comley, J. expanding the profile of KINASE PANELS. Drug Discovery World 2004, 45-56.
37. Glickman, J. F.; Schmid, A.; Ferrand, S. Scintillation Proximity Assays in High-Throughput Screening. Assay Drug Dev. Technol. 2008, 6, 433-455.
38. Kolb, A. J.; Kaplita, P. V.; Hayes, D. J.; Park, Y. W.; Pernell, C.; Major, J. S.; Mathis, G. Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence. Drug Discovery Today 1998, 3, 333-342.
39. Di Paolo, J. A.; Huang, T.; Balazs, M.; Barbosa, J.; Barck, K. H.; Bravo, B. J.; Carano, R. A. D.; Darrow, J.; Davies, D. R.; DeForge, L. E.; Diehl, L.; Ferrando, R.; Gallion, S. L.; Giannetti, A. M.; Gribling, P.; Hurez, V.; Hymowitz, S. G.; Jones, R.; Kropf, J. E.; Lee, W. P.; Maciejewski, P. M.; Mitchell, S. A.; Rong, H.; Staker, B. L.; Whitney, J. A.; Yeh, S.; Young, W. B.; Yu, C.; Zhang, J.; Reif, K.; Currie, K. S. Specific Btk Inhibition Suppresses B Cell- And Myeloid Cell-Mediated Arthritis. Nat. Chem. Biol. 2011, 7, 41–50.
40. Kenner, R. A.; Aboderin, A. A. New fluorescent probe for protein and nucleoprotein conformation. Binding of 7-(p-methoxybenzylamino)-4-nitrobenzoxadiazole to bovine trypsinogen and bacterial ribosomes. Biochemistry 1971, 10, 4433–4440.
41. Rasmussen, Soren G. F.; Carroll, F. I.; Maresch, M. J.; Jensen, A. D.; Tate, C. G.; Gether, U. Biophysical Characterization of the Cocaine Binding Pocket in the Serotonin Transporter Using a Fluorescent Cocaine Analogue as a Molecular Reporter. J. Biol. Chem. 2001, 276, 4717-4723.
42. Lou, Y.; Han, X.; Kuglstatter, A.; Kondru, R. K.; Sweeney, Z. K.; Soth, M.; McIntosh, J.; Litman, R.; Suh, J.; Kocer, B.; Davis, D.; Park, J.; Frauchiger, S.; Dewdney, N.; Zecic, H.; Taygerly, J. P.; Sarma, K.; Hong, J.; Hill, R. J.; Gabriel, T.; Goldstein, D. M.; Owens, T. D. Structure-based drug design of RN486, a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis. J. Med. Chem. 2015, 58, 512–516.
43. Sodhi, J. K.; Wong, S.; Kirkpatrick, D. S.; Liu, L.; Khojasteh, S. C.; Hop, Cornelis E. C. A.; Barr, J. T.; Jones, J. P.; Halladay, J. S. A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. Drug Metab. Dispos. 2015, 43, 908-915.
44. Chang, B. Y.; Huang, M. M.; Francesco, M.; Chen, J.; Sokolove, J.; Magadala, P.; Robinson, W. H.; Buggy, J. J. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res. Ther. 2011, 13, R115.
45. Hajbi, Y.; Suzenet, F.; Khouili, M.; Lazar, S.; Guillaumet, G. Polysubstituted 2,3- dihydrofuro[2,3-b]pyridines and 3,4-dihydro-2Hpyrano[2,3-b]pyridines via microwave- activated Inverse electron demand Diels-Alder reactions. Tetrahedron 2007, 63, 8286−8297.
46. Pellegatti, L.; Vedrenne, E.; Leger, J. M.; Jarry, C.; Routier, S. New heteroaromatic aminations on 5-aryl-1,2,4-triazines and 1,2,4,5- tetrazines by palladium catalysis. Tetrahedron 2010, 66, 4383−4389.
47. Bull, J. A.; Croft, R. A.; Davis, O. A.; Doran, R.; Morgan, K. F. Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry. Chem. Rev. 2016, 116, 12150– 12233.
48. Staudt, L. M.; Dunleavy, K.; Buggy, J. J.; Hedrick, E.; Lucas, N.; Pittaluga, S.;Jhavar, S.; Schmitz, R.; Williams, M.: Lih, J.; Jaffe, E. S.; Wilson, W. H. The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL. Blood 2011, 118: 2716.
49. Capek, P.; Vrabel, M.; Hasnik, Z.; Pohl, R.; Hocek, M. Aqueous-Phase Suzuki–Miyaura Cross- Coupling Reactions of Free Halopurine Bases. Synthesis 2006, 3515– 3526.
50. Brittelli, D. R.; Currie, K. S.; Darrow, J. W.; Kropf, J. E.; Lee, S. H.; Gallion, S. L.; Mitchell, S. A.; Pippin, D. A. I.; Blomgren, P. A. WO2006099075 A2.
51. Ernst, J. T.; Neubert, T.; Liu, M.; Sperry, S.; Zuccola, H.; Turnbull, A.; Fleck, B.; Kargo, W.; Woody, L.; Chiang, P.; Tran, D.; Chen, W.; Snyder, P.; Alcacio, T.; Nezami, A.; Reynolds, J.; Alvi, K.; Goulet, L.; Stamos, D. Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease. J. Med. Chem. 2014 57, 3382-3400.
52. Crawford, J. J.; Johnson, A. R.; Misner, D. L.; Belmont, L. D.; Castanedo, G.; Choy, R.; Coraggio, M.; Dong, L.; Eigenbrot, C.; Erickson, R.; Ghilardi, N.; Hau, J.; Katewa, A.; Kohli, P. B.; Lee, W.; Lubach, J. W.; McKenzie, B. S.; Ortwine, D. F.; Schutt, L.; Tay, S.; Wei, B.; Reif, K.; Liu, L.; Wong, H.; Young, W. B. Discovery of GDC-0853: A potent, selective, and noncovalent Bruton's tyrosine kinase inhibitor in early clinical development. J. Med. Chem. 2018, 61, 2227- 2245.